Voyager Therapeutics (VYGR) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Voyager Therapeutics (VYGR) was upgraded by Truist Financial Corporation to "strong-buy".
Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript [Seeking Alpha]
Voyager Therapeutics Conference: CEO Calls 2026 “Year of Tau,” Eyes BBB Capsid Clinic Debut [Yahoo! Finance]
Voyager Therapeutics (VYGR) had its "buy" rating reaffirmed by HC Wainwright. They now have a $25.00 price target on the stock.